Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review


Background: Subcutaneous immunoglobulin (SCIG) is effective treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Quality of life (QoL) increases following switch from intravenous administration to SCIG, but its correlation with clinical functioning is sparsely studied.

Aims of the study: The aim of this study is to evaluate the correlation between QoL and clinical functioning in CIDP patients treated with SCIG.

Methods: Danish patients with CIDP with a disease duration

Results: Of 92 eligible patients, 44 were included. QoL on the visual analogue scale (VAS) was 65% (range: 15-90) of the level of healthy controls (P = .03) and correlated to impaired gait function by 40-MWT and 6-SST. QoL correlated to RODS and ODSS, whereas there was no correlation with the MRC score.

Conclusions: In SCIG treated CIDP patients QoL is reduced and correlates to gait performance and disability.

Original languageEnglish
Book seriesActa Neurologica Scandinavica. Supplementum
Pages (from-to)637-640
Number of pages4
Publication statusPublished - Dec 2020

    Research areas

  • chronic inflammatory demyelinating polyneuropathy, quality of life, subcutaneous immunoglobulin, CIDP, MMN, VALUES

See relations at Aarhus University Citationformats

ID: 195425232